The Company manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Akorn, is a generic pharma company that has been remade by successful healthcare turnaround investor John Kapoor (Chariman of the Board). The major catalyst for this name, will be FDA approval of AKRX’s generic version of Vancocin (first to file, been in FDA limbo for many years). Even branded Vanco manufacturer, Viropharma, has hinted that they believe 2011 will be the year they finally lose their vanco monopoly, which will probably send AKRX to the $12 range (assuming they receive a 6 month exclusivity)
Generic Vanco trade- Long AKRX, Short VPHM